Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of Clinical Oncology
The interpretation of genomic sequencing data is complex. Not all tumors have alterations within therapeutically targetable or actionable genes, and not all alterations detected within a therapeutically actionable gene may confer sensitivity to genomic biomarker–linked therapies. ASCO’s expert panel provides a provisional opinion, giving guidance on using genomic sequencing to inform treatment selection for patients with metastatic or advanced solid tumors.
Hematology/Oncology March 1st 2022
ASH Clinical News
To define the spectrum of alterations common at relapse, the researchers in this study performed integrated profiling of 136 relapsed pediatric AML cases with RNA sequencing (RNA-seq), whole-genome sequencing, and target-capture sequencing. In addition, well-characterized fusion oncoproteins were identified, as were somatic mutations in UBTF (upstream binding transcription factor). See the results from the late-breaking abstract being presented at the ASH Annual Meeting & Exhibition.
Hematology December 7th 2021
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS